The natural history of chronic obstructive pulmonary disease

European Respiratory Journal

Volumn 27, Issue 3, 2006, Pages 627-643

  Mannino, D M ^a   Watt, G ^d   Hole, D ^d   Gillis, C ^d   Hart, C ^d   McConnachie, A ^d   Smith, G Davey ^e   Upton, M ^f   Hawthorne, V ^b   Sin, D D ^g   Man, S F P ^g   Van Eeden, S ^g   Mapel, D W ^c   Vestbo, J ^h,i  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c LOVELACE CLINIC FOUNDATION   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f Woodlands Family Medical Centre   (United Kingdom)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; EXERCISE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFLAMMATORY DISEASE; LUNG FUNCTION; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SYMPTOMATOLOGY; UNITED STATES;

CARDIOVASCULAR DISEASES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33644867170     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00024605     Document Type: Review

References (112)

1. Chen JC, Mannino DM. Worldwide epidemiology of chronic obstructive pulmonary disease. Curr Opin Pulm Med 1999; 5: 93-99.
2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Morb Mortal Wkly Rep 2002; 51: 1-16.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
5. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519.
6. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121: Suppl. 5, 121S-126S.
7. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 462-469.
8. Smith KR, Mehta S. The burden of disease from indoor air pollution in developing countries: comparison of estimates. Int J Hyg Environ Health 2003; 206: 279-289.
9. Romieu I, Trenga C. Diet and obstructive lung diseases. Epidemiol Rev 2001; 23: 268-287.
10. Shaheen SO, Barker DJ, Holgate ST. Do lower respiratory tract infections in early childhood cause chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1995; 151: 1649-1651.
11. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001; 2: 20-26.
12. Mayer AS, Newman LS. Genetic and environmental modulation of chronic obstructive pulmonary disease. Respir Physiol 2001; 128: 3-11.
13. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80: 501-522.
14. O'Byrne PM, Postma DS. The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Asthma Research Group. Am J Respir Crit Care Med 1999; 159: S41-S63.
15. Sparrow D, O'Connor G, Weiss ST. The relation of airways responsiveness and atopy to the development of chronic obstructive lung disease. Epidemiol Rev 1988; 10: 29-47.
16. Meyer PA, Mannino DM, Redd SC, Olson DR. Characteristics of adults dying with COPD. Chest 2002; 122: 2003-2008.
17. Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999; 14: 892-896.
18. World Health Organization. The GOLD global strategy for the management and prevention of COPD, 2001. www.goldcopd.org/Guidelineitem.asp? 1=2& 2=1&intld=996 Last accessed November 21, 2005. Last updated September 2005.
19. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-273.
20. Kohler D, Fischer J, Raschke F, Schonhofer B. Usefulness of GOLD classification of COPD severity. Thorax 2003; 58: 825.
21. Peto R, Speizer FE, Cochrane AL, et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983; 128: 491-500.
22. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309-1314.
23. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
24. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat, 1 1994; Jul: 1-407.
25. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163: 1475-1480.
26. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and functional limitation: data from the Third National Health and Nutrition Examination. J Intern Med 2003; 254: 540-547.
27. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114: 758-762.
28. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 10-14.
29. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388-393.
30. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
31. Burrows B. Airways obstructive diseases: pathogenetic mechanisms and natural histories of the disorders. Med Clin North Am 1990; 74: 547-559.
32. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267-1271.
33. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
34. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21: Suppl. 41, 46s-53s.
35. Sethi S. Bacterial infection and the pathogenesis of COPD. Chest 2000; 117: Suppl. 1, 286S-291S.
36. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.
37. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471.
38. Sheffer AL, Taggart VS. The National Asthma Education Program. Expert panel report guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. Med Care 1993; 31: Suppl. 3, MS20-MS28.
39. Hawthorne VM, Watt GCM, Hart CL, Hole DJ, Smith GD, Gillis CR. Cardiorespiratory disease in men and women in urban Scotland. Baseline characteristics of the Renfrew/Paisley (MIDSPAN) study population. Scott Med J 1995; 40: 102-107.
40. Watt GCM, Hart CL, Hole DJ, Smith GD, Gillis CR, Hawthorne VM. Risk factors for cardiorespiratory and all cause mortality in men and women in urban Scotland: 15-year follow up. Scott Med J 1995; 40: 108-112.
41. Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20-year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000; 321: 88-92.
42. University of Glasgow, MIDSPAN. http://www.gla.ac.uk/faculties/medicine/midspan Last updated and accessed November 21, 2005.
43. Hole DJ, Watt GCM, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-715.
44. Upton MN, Ferrell CM, Bidwell C, et al. Improving the quality of spirometry in an epidemiological study. Public Health 2000; 114: 353-360.
45. Upton MN, Davey-Smith G, McConnachie A, Hart CL, Watt GC. Maternal and personal cigarette smoking synergize to increase airflow limitation in adults. Am J Respir Crit Care Med 2004; 169: 479-487.
46. Ebi-Kryston KL, Hawthorne VM, Rose G, et al. Breathlessness, chronic bronchitis and reduced pulmonary function as predictors of cardiovascular disease mortality among men in England, Scotland and the United States. Int J Epidemiol 1989; 18: 84-88.
47. Hanlon P, Walsh D, Whyte BW, Scott SN, Lightbody P, Gilhooly ML. Hospital use by an ageing cohort: an investigation into the association between biological, behavioural and social risk markers and subsequent hospital utilisation. J Public Health Med 1998; 20: 467-476.
48. Hole DJ, Gillis CR, Chopra C, Hawthorne VM. Passive smoking and cardiorespiratory health in a general population in the west of Scotland. BMJ 1989; 299: 423-427.
49. Upton MN, Watt GCM, Davey-Smith G, McConnachie A, Hart CL. Permanent effects of maternal smoking on offsprings' lung function. Research letter. Lancet 1998; 352: 453.
50. Gunnell D, Whitley E, Upton MN, McConnachie A, Smith GD, Watt GC. Associations of height, leg length, and lung function with cardiovascular risk factors in the Midspan Family Study. J Epidemiol Community Health 2003; 57: 141-146.
51. Pearson TA, Mensah GA, Alexander RW, et al. Centers for Disease Control and Prevention. Markers of inflammation and cardiovascular disease: applications to clinical and public health practice: A statement from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
52. O'Reilly DStJ, Upton MN, Caslake MJ, et al. Plasma C-reactive protein concentration demonstrates a direct relationship between systemic inflammation and social deprivation. Heart 2005: (In press).
53. Sattar N, McConnachie A, O'Reilly D, et al. Inverse association between birth weight and C-reactive protein concentrations in the Midspan Family Study. Arterioscler Thromb Vasc Biol 2004; 24: 583-587.
54. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
55. Michaud CM, Murray CJ, Bloom BR. Burden of disease - implications for future research. JAMA 2001; 285: 535-539.
56. Camilli AF, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133: 795-800.
57. Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research Group, Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339.
58. Sin DD, Wu L, Man SFP. The relationship between reduced lung function and cardiovascular mortality. A population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959.
59. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
60. Lusis A J. Atherosclerosis. Nature 2000; 407: 233-241.
61. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
62. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
63. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999; 130: 933-937.
64. Verma S, Li SH, Badiwala MV, Weisel RD, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-1896.
65. Verma S, Yeh ET, Wang CH, et al. C-reactive protein and atherothrombosis - beyond a biomarker: an actual partaker of lesion formation. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1253-RI256.
66. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
67. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
68. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
69. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
70. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-873.
71. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177.
72. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
73. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-2415.
74. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
75. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-18.
76. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
77. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-580.
78. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
79. Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF. Phagocytosis of small carbon particles by alveolar macrophages stimulates the release of PMN from the bone marrow. Am J Respir Crit Care Med 1997; 155: 1441-1447.
80. van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000; 15: 915-921.
81. Tan WC, Qui D, Liam BL, et al. The human bone marrow response to fine particulate air pollution. Am J Respir Crit Care Med 2000; 161: 1213-1217.
82. Terashima T, Wiggs B, English D, Hogg JC, van Eeden SF. Phagocytosis of small carbon particles by alveolar macrophages stimulates the release of PMN from the bone marrow. Am J Respir Crit Care Med 1997; 155: 1441-1447.
83. van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000; 15: 915-921.
84. van Eeden SF, Hogg JC. Systemic inflammatory response induced by particulate matter air pollution: the importance of bone-marrow stimulation. J Toxicol Environ Health A 2002; 65: 1597-1613.
85. Mukae H, Vincent R, Quinlan K, et al. The effect of repeated exposure to particulate air pollution (PM10) on the bone marrow. Am J Respir Crit Care Med 2001; 163: 201-209.
86. Suwa TJ, Hogg JC, Quinlan KB, Ohgami A, Vincent R, van Eeden SF. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2000; 39: 935-942.
87. Mukae HJ, Hogg JC, English D, Vincent R, van Eeden SF. Phagocytosis of particulate air pollutants by human alveolar macrophages stimulates the bone marrow. Am J Physiol Lung Cell Mol Physiol 2000; 279: L924-L931.
88. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
89. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
90. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
91. Engstrom G, Wollmer P, Hedblad B, Juul-Moller S, Valind S, Janzon L. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914," Malmo, Sweden. Circulation 2001; 103: 3086-3091.
92. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
93. Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002; 51: 300-303.
94. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-controlled study in a health maintenance organization. Arch Intern Med 2000; 160: 2653-2658.
95. Mapel DW, Picchi MA, Hurley JS, et al. Utilization in chronic obstructive pulmonary disease: patient characteristics and diagnostic evaluation. Chest 2000; 117: 346S-353S.
96. U.S. Department of Health and Human Services. Other Effects: Peptic Ulcer Disease. In: The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA, U.S Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004; pp. 804-817.
97. Mapel DW, Shainline M, Paez K, Gunter M. Hospital, pharmacy, and outpatient costs for osteoarthritis and chronic back pain. J Rheumatol 2004; 31: 573-583.
98. Mapel DW, Roberts MS, Hurley JS, et al. A prospective study of clinical factors associated with increased medical costs in COPD. Am J Respir Crit Care Med 2004; 169: A223.
99. Mapel DW, McMillan GP, Brightwell J, et al. Predictors of increased healthcare costs in COPD: a prospective analysis. Am J Respir Crit Care Med 2001; 163: A508.
100. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-994.
101. Rijcken B, Britton J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir Mon 1998; 7: 74-83.
102. Lebowitz MD, Morse JO, Knudson RJ, Barbee R, Burrows B. Respiratory disorders in Tucson: preliminary observations. Ariz Med 1975; 32: 329-331.
103. Hospers JJ, Rijcken B, Schouten JP, Postma DS, Weiss ST. Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Am J Epidemiol 1999; 150: 482-491.
104. Carrozzi L, Giuliano G, Viegi G, et al. The Po River Delta epidemiological study of obstructive lung disease: sampling methods, environmental and population characteristics. Eur J Epidemiol 1990; 6: 191-200.
105. Vestbo J, Prescott E, Lange P, The Copenhagen City Heart Study Group, Association of chronic mucus hypersecretion with FEV1 decline and COPD morbidity. Am J Respir Crit Care Med 1996; 153: 1530-1535.
106. de Marco R, AccordiNI S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125.
107. Crenesse D, Berlioz M, Bourrier T, Albertini M. Spirometry in children aged 3 to 5 years: reliability of forced expiratory manoeuvres. Pediatr Pulmonol 2001; 32: 56-61.
108. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am J Respir Crit Care Med 2001; 144: 1202-1218.
109. Edwards CA, Osman LM, Godden DJ, Campbell DM, Douglas JG. Relationship between birth weight and adult lung function: controlling for maternal factors. Thorax 2003; 58: 1061-1065.
110. Gold DR, Wang X, Wypij D, Spizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on the pulmonary function in adolescent boys and girls. N Engl J Med 1996; 335: 931-937.
111. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 1951; 41: 279-281.
112. Vermeire PA, Pride NB. A "splitting" look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 1991; 4: 490-496.